Research Projects (Third party funds)

Corona VAC

Proof-of-concept Studie eines SARS-CoV-2 Impfstoffs mit rekominantem Spike-Protein

Since the beginning of the SARS-CoV-2 outbreak, many groups are racing to develop a prophylactic vaccine by using several approaches including mRNA, DNA and live viral vectors. The main aims of the project are: (i) to provide the proof-of-concept for a CDA-adjuvanted intranasal S-based vaccine by demonstrating its capacity to promote the elicitation of humoral responses in vivo, which are able to neutralize the virus and protect vaccinated animals against SARS-CoV-2; (ii) to exploit in silico algorithms to generate a synthetic S variant with optimized sequences for B and T cell epitopes able to promote responses cross-recognizing SARS-CoV-2 variants and potentially SARS and MERS; (iii) to develop a GMP compliant process for the manufacturing of the resulting antigen; (iv) to perform a first scientific advice with Paul-Ehrlich-Institut to define the regulatory pathway for this vaccine; and (v) to perform a cost calculation and time planning for the activities required to perform first in man studies of the vaccine. The resulting work flow can be exploited for other emerging pandemic threads.


Funding agency

Ministry for Science and Culture of Lower Saxony

PrintSend per emailShare